Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:AKRO NASDAQ:SYRE NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$74.08+3.1%$68.15$47.86▼$107.37$3.99B0.28533,971 shs617,614 shsAKROAkero Therapeutics$49.38-1.4%$51.95$21.34▼$58.40$4.01B-0.281.04 million shs2.19 million shsSYRESpyre Therapeutics$16.95+0.5%$16.26$10.91▼$40.26$1.02B2.82505,881 shs536,949 shsVKTXViking Therapeutics$40.03-0.5%$31.10$18.92▼$81.73$4.52B0.674.64 million shs3.29 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+3.09%+5.08%+4.78%+26.03%+22.91%AKROAkero Therapeutics-1.42%-2.14%-7.87%+27.04%+107.83%SYRESpyre Therapeutics+0.53%+11.81%+4.63%+11.66%-31.46%VKTXViking Therapeutics-0.52%+5.65%+26.56%+40.80%-31.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.836 of 5 stars3.60.00.00.02.42.50.0AKROAkero Therapeutics3.9466 of 5 stars3.52.00.04.73.30.80.0SYRESpyre Therapeutics3.1311 of 5 stars3.62.00.00.03.62.50.6VKTXViking Therapeutics4.083 of 5 stars3.51.00.04.73.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$114.3154.30% UpsideAKROAkero Therapeutics 3.00Buy$81.5765.19% UpsideSYRESpyre Therapeutics 3.29Buy$53.40215.04% UpsideVKTXViking Therapeutics 3.00Buy$86.92117.14% UpsideCurrent Analyst Ratings BreakdownLatest SYRE, ACLX, AKRO, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.008/4/2025AKROAkero TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy8/4/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/4/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$76.007/31/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$93.00 ➝ $133.007/24/2025VKTXViking TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$125.00 ➝ $122.007/24/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$31.00 ➝ $38.006/25/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.006/17/2025ACLXArcellxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$110.006/16/2025ACLXArcellxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.005/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.00(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M38.06N/AN/A$7.07 per share10.48AKROAkero TherapeuticsN/AN/AN/AN/A$12.82 per shareN/ASYRESpyre Therapeutics$890K1,150.31N/AN/A$4.97 per share3.41VKTXViking TherapeuticsN/AN/AN/AN/A$7.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%N/AAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%N/ASYRESpyre Therapeutics-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%N/AVKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest SYRE, ACLX, AKRO, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/5/2025Q2 2025SYRESpyre Therapeutics-$0.73-$0.49+$0.24-$0.49N/AN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81AKROAkero Therapeutics0.0212.6616.80SYRESpyre TherapeuticsN/A6.496.49VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%AKROAkero TherapeuticsN/ASYRESpyre Therapeutics80.39%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%AKROAkero Therapeutics7.07%SYRESpyre Therapeutics15.43%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableSYRESpyre Therapeutics7360.40 million51.08 millionOptionableVKTXViking Therapeutics20112.44 million107.84 millionOptionableSYRE, ACLX, AKRO, and VKTX HeadlinesRecent News About These CompaniesAigen Investment Management LP Purchases Shares of 13,780 Viking Therapeutics, Inc. (NASDAQ:VKTX)August 15 at 4:59 AM | marketbeat.comViking Therapeutics Earns Relative Strength Rating Upgrade; Hits Key BenchmarkAugust 14 at 10:36 PM | msn.comThe 3 Things That Matter for Viking Therapeutics NowAugust 13 at 4:10 AM | fool.comIf You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have TodayAugust 12, 2025 | msn.comConnor Clark & Lunn Investment Management Ltd. Purchases 222,293 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)August 12, 2025 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)August 11, 2025 | theglobeandmail.comViking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735August 11, 2025 | finance.yahoo.comNew Age Alpha Advisors LLC Buys New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)August 9, 2025 | marketbeat.comRaiffeisen Bank International AG Buys 13,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)August 6, 2025 | marketbeat.comHarbour Investments Inc. Boosts Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)August 6, 2025 | marketbeat.comCetera Investment Advisers Raises Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)August 5, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Buys Shares of 8,519 Viking Therapeutics, Inc. (NASDAQ:VKTX)August 5, 2025 | marketbeat.comViking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?August 4, 2025 | zacks.comNJ State Employees Deferred Compensation Plan Buys 10,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)August 4, 2025 | marketbeat.com2 Beaten-Down Stocks With Incredible Upside PotentialAugust 3, 2025 | fool.com2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top AnalystsAugust 3, 2025 | fool.comVictory Capital Management Inc. Has $317,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)August 3, 2025 | marketbeat.comShort Interest in Viking Therapeutics, Inc. (NASDAQ:VKTX) Expands By 88,996.6%August 2, 2025 | marketbeat.comIs Viking Therapeutics the Next Big Biotech Bet?August 1, 2025 | fool.comAllianz Asset Management GmbH Sells 35,986 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)August 1, 2025 | marketbeat.comViking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 TrialJuly 31, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSYRE, ACLX, AKRO, and VKTX Company DescriptionsArcellx NASDAQ:ACLX$74.08 +2.22 (+3.09%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$74.02 -0.06 (-0.09%) As of 08/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Akero Therapeutics NASDAQ:AKRO$49.38 -0.71 (-1.42%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$48.07 -1.31 (-2.65%) As of 08/15/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Spyre Therapeutics NASDAQ:SYRE$16.95 +0.09 (+0.53%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$16.50 -0.45 (-2.65%) As of 08/15/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Viking Therapeutics NASDAQ:VKTX$40.03 -0.21 (-0.52%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$40.70 +0.67 (+1.67%) As of 08/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access